Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29276022

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Feb
First author
O'Connor OA

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Feb;19(2):162-163. doi: 10.1016/S1470-2045(17)30913-0.
    note
    Source null
    related pmid
    29276023
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Mar;19(3):e137. doi: 10.1016/S1470-2045(18)30159-1.
    note
    Source null
    related pmid
    29508761
    relationship
    Erratum in
  3. citation
    Ann Transl Med. 2018 Jun;6(11):237. doi: 10.21037/atm.2018.05.39.
    note
    Source null
    related pmid
    30023400
    relationship
    Comment in
  4. citation
    Ann Transl Med. 2018 Jun;6(11):238. doi: 10.21037/atm.2018.05.40.
    note
    Source null
    related pmid
    30023401
    relationship
    Comment in

Authors and identifiers

  1. name
    O'Connor OA
    type
    Author
  2. name
    Lue JK
    type
    Author
  3. name
    Sawas A
    type
    Author
  4. name
    Amengual JE
    type
    Author
  5. name
    Deng C
    type
    Author
  6. name
    Kalac M
    type
    Author
  7. name
    Falchi L
    type
    Author
  8. name
    Marchi E
    type
    Author
  9. name
    Turenne I
    type
    Author
  10. name
    Lichtenstein R
    type
    Author
  11. name
    Rojas C
    type
    Author
  12. name
    Francescone M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    O'Connor OA
    type
    Author
  2. name
    Lue JK
    type
    Author
  3. name
    Sawas A
    type
    Author
  4. name
    Amengual JE
    type
    Author
  5. name
    Deng C
    type
    Author
  6. name
    Kalac M
    type
    Author
  7. name
    Falchi L
    type
    Author
  8. name
    Marchi E
    type
    Author
  9. name
    Turenne I
    type
    Author
  10. name
    Lichtenstein R
    type
    Author
  11. name
    Rojas C
    type
    Author
  12. name
    Francescone M
    type
    Author
bibliography ids
  1. nci-bib-27c28c56d60fc6ec43d5d2eb
book metadata
content sha256
979927260fde996ff3f78339949524c3347859d9dd229274affa8aef2329aaae
document type
citation
dois
  1. 10.1016/S1470-2045(17)30912-9
electronic publication date
display
2017 Dec 21
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:29276022
immutable id
pubmed:29276022@979927260fde996ff3f78339949524c3347859d9dd229274affa8aef2329aaae
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
257-266
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Feb;19(2):162-163. doi: 10.1016/S1470-2045(17)30913-0.
    note
    Source null
    related pmid
    29276023
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Mar;19(3):e137. doi: 10.1016/S1470-2045(18)30159-1.
    note
    Source null
    related pmid
    29508761
    relationship
    Erratum in
  3. citation
    Ann Transl Med. 2018 Jun;6(11):237. doi: 10.21037/atm.2018.05.39.
    note
    Source null
    related pmid
    30023400
    relationship
    Comment in
  4. citation
    Ann Transl Med. 2018 Jun;6(11):238. doi: 10.21037/atm.2018.05.40.
    note
    Source null
    related pmid
    30023401
    relationship
    Comment in
outcomes validated
false
pmid
29276022
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
30e05a32cce6ce5af3cac8aef8eef5266e87fd77a13cd40cd2ddc238338bbd3d
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 Feb
precision
month
year
2018
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Comparative Study
  4. Journal Article
  5. Multicenter Study
  6. Research Support, N.I.H., Extramural
  7. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29276022/
title
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

Preserved source evidence · Not medical advice